Anti-interferon-alpha-receptor monoclonal antibody 64G12

Drug Profile

Anti-interferon-alpha-receptor monoclonal antibody 64G12

Alternative Names: 64G12; 64G12 antibody; Anti-interferon-alpha-receptor antibody

Latest Information Update: 26 Jul 2002

Price : $50

At a glance

  • Originator Pharma Pacific Management
  • Developer Nonindustrial source; Pharma Pacific Management
  • Class Monoclonal antibodies
  • Mechanism of Action Interferon receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Autoimmune disorders; Transplant rejection

Most Recent Events

  • 30 Jan 2001 Coulter Pharmaceutical has been acquired by Corixa Corporation
  • 04 Jun 1999 Preclinical development for Autoimmune disorders in Australia (Unknown route)
  • 04 Jun 1999 Preclinical development for Transplant rejection in Australia (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top